Drug repurposing and adverse event prediction using high‐throughput literature analysis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Drug repurposing is the process of using existing drugs in indications other than the ones they were originally designed for. It is an area of significant recent activity due to the mounting costs of traditional drug development and scarcity of new chemical entities brought to the market by bio‐pharmaceutical companies. By selecting drugs that already satisfy basic toxicity, ADME and related criteria, drug repurposing promises to deliver significant value at reduced cost and in dramatically shorter time frames than is normally the case for the drug development process. The same process that results in drug repurposing can also be used for the prediction of adverse events of known or novel drugs. The analytics method is based on the description of the mechanism of action of a drug, which is then compared to the molecular mechanisms underlying all known adverse events. This review will focus on those approaches to drug repurposing and adverse event prediction that are based on the biomedical literature. Such approaches typically begin with an analysis of the literature and aim to reveal indirect relationships among seemingly unconnected biomedical entities such as genes, signaling pathways, physiological processes, and diseases. Networks of associations of these entities allow the uncovering of the molecular mechanisms underlying a disease, better understanding of the biological effects of a drug and the evaluation of its benefit/risk profile. In silico results can be tested in relevant cellular and animal models and, eventually, in clinical trials. WIREs Syst Biol Med 2011 3 323–334 DOI: 10.1002/wsbm.147 This article is categorized under: Analytical and Computational Methods > Computational Methods
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
A side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647 · cited 2×
“…[PDSP Ki Database, 65 Protein Data Bank (PDB), 66 KEGG, 67 Reactome, 68 NCI-Nature Pathway Interaction Database, 69 Drug-Bank, 70 and MATADOR 71 ] and drug–ligand interactions (GLIDA, 72 PharmGKB, 73,74 Comparative Toxi-cogenomics Database (CTD), 75 and BindingDB 76 ) are incorporated in…”
Cited by
Data-driven prediction of drug effects and interactions
Tatonetti, N. P., Ye, P. P., Daneshjou, R., & Altman, R. B. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003377 · Cited by 936
“Nonetheless, recent work in chemical biology has used the SIDER (a text-mined database of drug package inserts) to good effect ( 12 , 13 , 20 ).”
MethodNovel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.50 · Cited by 393
Recent advances in biomedical literature mining
Zhao, S., Su, C., Lu, Z., & Wang, F. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa057 · Cited by 134
“It is particularly promising in a number of applications in pharmaceutical industry such as drug development [149–151],drugrepurposing[144,150,152–157]andpharmacovig-ilance [152, 158–160], which are further highlighted below.”
BackgroundLiterature Based Discovery: Models, methods, and trends
Henry, S., & McInnes, B. T. (2017) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2017.08.011 · Cited by 121
Metadata
- Authors
- Deftereos, S. N., Andronis, C., Friedla, E. J., Persidis, A., & Persidis, A.
- Venue
- WIREs Systems Biology and Medicine
- Publisher
- Wiley
- Published
- 2011-02-16
- Volume
- 3
- Issue
- 3
- Pages
- 323-334
- ISSN
- 1939-005X (ISSN-L)
- 1939-5094
- OpenAlex
- W1995580819
- Cited by
- 118
- References
- 6
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug repurposing and adverse event prediction using high‐throughput literature analysis. https://app.cochat.ai/papers/10.1002/wsbm.147
- The paper
- Deftereos, S. N., Andronis, C., Friedla, E. J., Persidis, A., & Persidis, A. (2011). Drug repurposing and adverse event prediction using high‐throughput literature analysis. WIREs Systems Biology and Medicine. https://doi.org/10.1002/wsbm.147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.